NNC0721-8060

NNC0721-8060 is a long-acting gastric inhibitory polypeptide (GIP) receptor agonist currently under development by Novo Nordisk for the treatment of obesity and overweight. As a GIP receptor agonist, it targets the GIP receptor to modulate energy balance, insulin secretion, and lipid metabolism. The drug is being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and weight-loss efficacy in healthy adults with overweight or obesity, often in comparison to semaglutide and placebo. This asset represents a key component of Novo Nordisk's next-generation obesity pipeline, exploring the therapeutic potential of GIPR agonism as a standalone or combination therapy to complement their established GLP-1 receptor agonist portfolio.